IHH Healthcare - DBS Research 2016-11-25: New hospitals to drive long term growth

IHH Healthcare - DBS Vickers 2016-11-25: New hospitals to drive long term growth IHH HEALTHCARE BERHAD Q0F.SI

IHH Healthcare - New hospitals to drive long term growth

  • 3Q16 below expectations on higher expenses.
  • Revenue growth remains strong (3Q16 +18%).
  • Potential impact from depreciation of Turkish Lyra and MYR, partially mitigated by stronger SGD against MYR.
  • TP lowered to RM7.15.

Gleneagles Hong Kong leads IHH’s ‘Growth 2.0’. 

  • The long awaited Gleneagles HK, targeted to open by March / April 2017 is on track. We remain positive on the prospects of Gleneagles HK. 
  • New hospitals targeted to open in 2017 are on track as well - Acibadem Altunizade in early 2017, and Parkway Hospital in Chengdu by the end of 2017. We believe IHH Healthcare (IHH)’s medium-term growth will likely be contributed by new hospitals largely in China and India. 
  • Management intends to add c.1,000 new beds (includes Gleneagles HK) by the end of 2017.

9M16 results below expectations. 

  • IHH’s core net profit (excluding forex and one-off gains) fell 6% y-o-y to RM643m, largely due to higher operating expenses, resulting in a compression of core EBIT margins from 17% in 9M15 to 14% in 9M16. 
  • Key positives: 
    1. strong revenue growth, 
    2. lower start-up costs from new hospitals in Malaysia, and 
    3. Malaysia has picked up. 
  • Key negatives: 
    1. margin compression, 
    2. higher preoperating costs, and 
    3. depreciation of Turkish Lyra and MYR.

Near term startup costs, but longer term prospects positive. 

  • 3Q results confirm our view that near term earnings growth could moderate due to : 
    1. start-up/pre-operating costs of new hospitals, and 
    2. macroeconomic headwinds. 
  • That said, revenue growth still remains resilient amid market uncertainties. We believe any share price weakness offers a good entry opportunity for medium- to long-term growth prospects. 
  • We like IHH for its geographical diversification and recognised presence as a premium healthcare player.


  • We maintain our BUY rating with TP of RM7.15, based on SOTP valuation methodology. 
  • Key catalysts are 
    1. positive performance and shorter-than-expected gestation period of Gleneagles HK and the other new hospitals, 
    2. better-than-expected performance despite macroeconomic headwinds, and 
    3. positive developments in new markets, such as India.

Key Risks to Our View

  1. Economic slowdown; 
  2. lower-than-expected performance, especially in new markets; and 
  3. government policy changes.

Rachel Lih Rui Tan DBS Vickers | Andy Sim CFA DBS Vickers | http://www.dbsvickers.com/ 2016-11-25
DBS Vickers SGX Stock Analyst Report BUY Maintain BUY 7.15 Down 7.600